Search Results - "Lathan, B"

Drug monitoring detects under- and overdosing in patients receiving 5-fluorouracil-containing chemotherapy—results of a prospective, multicenter German observational study by Li, M., Mindt, S., Lück, A., Hutzschenreuter, U., Kollendt, M., Lathan, B., Zöller, T., Frank-Gleich, S., Lorentz, C., Lamberti, C., Sick, C., Zingerle, M., Tesch, H., Stein, W., Hebart, H., Stosiek, C., Sandner, R., Fries, S., Burkholder, I., Hofheinz, R.-D.

“…Body surface area (BSA)-based dosing of 5-fluorouracil (5-FU) results in marked inter-individual variability in drug levels, whereas determination of plasma…”
Get full text

Fatigue in long-term survivors of Hodgkin's lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG) by RÜFFER, J. U, FLECHTNER, H, TRALLS, P, JOSTING, A, SIEBER, M, LATHAN, B, DIEHL, V

“…Although treatment regimens for Hodgkin's lymphoma have become more sophisticated, little is known about the prevalence of fatigue in long-term survivors…”
Get full text

Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment by Rueffer, U., Breuer, K., Josting, A., Lathan, B., Sieber, M., Manzke, O., Grotenhermen, F.-J., Tesch, H., Bredenfeld, H., Koch, P., Nisters-Backes, H., Wolf, J., Engert, A., Diehl, V.

“…Summary Infertility after treatment of patients with Hodgkin's disease (HD) is considered as a side effect of alkylating agent containing chemotherapy regimens…”
Get full text

BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group by Diehl, V, Franklin, J, Hasenclever, D, Tesch, H, Pfreundschuh, M, Lathan, B, Paulus, U, Sieber, M, Rueffer, J U, Sextro, M, Engert, A, Wolf, J, Hermann, R, Holmer, L, Stappert-Jahn, U, Winnerlein-Trump, E, Wulf, G, Krause, S, Glunz, A, von Kalle, K, Bischoff, H, Haedicke, C, Duehmke, E, Georgii, A, Loeffler, M

“…The HD9 trial aims to evaluate whether moderate dose escalation and/or acceleration of standard polychemotherapy is beneficial for advanced-stage Hodgkin's…”
Get more information

Low-Dose Radiation Is Sufficient for the Noninvolved Extended-Field Treatment in Favorable Early-Stage Hodgkin’s Disease: Long-Term Results of a Randomized Trial of Radiotherapy Alone by DÜHMKE, Eckhart, FRANKLIN, Jeremy, LATHAN, Bernd, RÜFFER, Ulrich, SIEBER, Markus, WOLF, Jürgen, ENGERT, Andreas, GEORGII, Axel, STAAR, Susanne, HERRMANN, Richard, BEYKIRCH, Maria, KIRCHNER, Hartmut, PFREUNDSCHUH, Michael, EMMINGER, Adelheid, GREIL, Richard, FRITSCH, Esther, KOCH, Peter, DROCHTERT, Angelika, BROSTEANU, Oana, HASENCLEVER, Dirk, LOEFFLER, Markus, DIEHL, Volker, SEHLEN, Susanne, WILLICH, Norman, RÜHL, Ursula, MÜLLER, Rolf-Peter, LUKAS, Peter, ATZINGER, Anton, PAULUS, Ursula

“…To show that radiotherapy (RT) dose to the noninvolved extended field (EF) can be reduced without loss of efficacy in patients with early-stage Hodgkin's…”
Get full text

BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease by Diehl, V., Sieber, M., Rüffer, U., Lathan, B., Hasenclever, D., Pfreundschuh, M., Loeffler, M., Lieberz, D., Koch, P., Adler, M., Tesch, H.

“…Purpose: At present, treatment results for patients with advanced-stage Hodgkin's disease remain unsatisfactory. Standard chemotherapy M(C)OPP (nitrogen…”
Get full text

Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group by Pfreundschuh, M G, Rueffer, U, Lathan, B, Schmitz, N, Brosteanu, O, Hasenclever, D, Haas, R, Kirchner, H, Koch, P, Kuse, R

“…A prospective phase II study was conducted to evaluate the efficacy of dexamethasone, carmustine, etoposide, cytarabine, and melphalan (Dexa-BEAM) as salvage…”
Get more information

Moderate Dose Escalation for Advanced Stage Hodgkin's Disease Using the Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Scheme and Adjuvant Radiotherapy: A Study of the German Hodgkin's Lymphoma Study Group by Tesch, H., Diehl, V., Lathan, B., Hasenclever, D., Sieber, M., Rüffer, U., Engert, A., Franklin, J., Pfreundschuh, M., Schalk, K.P., Schwieder, G., Wulf, G., Dölken, G., Worst, P., Koch, P., Schmitz, N., Bruntsch, U., Tirier, C., Müller, U., Loeffler, M.

“…The BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) regimen, a rearranged and accelerated version of…”
Get full text

Moderate Dose Escalation for Advanced Stage Hodgkin’s Disease Using the Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Scheme and Adjuvant Radiotherapy: A Study of the German Hodgkin’s Lymphoma Study Group by Tesch, H., Diehl, V., Lathan, B., Hasenclever, D., Sieber, M., Rüffer, U., Engert, A., Franklin, J., Pfreundschuh, M., Schalk, K.P., Schwieder, G., Wulf, G., Dölken, G., Worst, P., Koch, P., Schmitz, N., Bruntsch, U., Tirier, C., Müller, U., Loeffler, M.

“…The BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) regimen, a rearranged and accelerated version of…”
Get full text

BEACOPP: A new regimen for advanced Hodgkin's disease by Diehl, V., Franklin, J., Hasenclever, D., Tesch, H., Pfreundschuh, M., Lathan, B., Paulus, U., Sieber, M., Rüffer, J.-U., Sextro, M., Engert, A., Wolf, J., Hermann, R., Holmer, L., Stappert-Jahn, U., Winnerlein-Trump, E., Wulf, G., Krause, S., Glunz, A., von Kalle, K., Bischoff, H., Haedicke, C., Dühmke, E., Georgii, A., Loeffler, M.

“…The BEACOPP chemotherapy regimen for advanced Hodgkin's disease employs a rearranged schedule permitting a shortened three-week cycle. With haematological…”
Get full text

Dose escalation of cytotoxic drugs using haematopoietic growth factors: A randomized trial to determine the magnitude of increase provided by GM-CSF by Pfreundschuh, M., Hasenclever, D., Loeffler, M., Ehninger, G., Schmitz, N., Kirchner, H., Koch, P., Lathan, B., Rueffer, U., Sextro, M., Franklin, J., Tesch, H., Diehl, V.

“…Background The magnitude of chemotherapy dose escalation made possible by the use of recombinant haematopoietic growth factors has not been quantified in a…”
Get full text

Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease by Diehl, Volker, Franklin, Jeremy, Pfreundschuh, Michael, Lathan, Bernd, Paulus, Ursula, Hasenclever, Dirk, Tesch, Hans, Herrmann, Richard, Dörken, Bernd, Müller-Hermelink, Hans-Konrad, Dühmke, Eckhardt, Loeffler, Markus

“…Advanced Hodgkin's disease is difficult to control or cure with chemotherapy. This large trial compared three regimens, one of which contained more than the…”
Get full text

Ruminal nitrogen disappearance from sod-seeded cereal grain forages in Northern Arkansas by Coblentz, Wayne K, Coffey, Kenneth P, Turner, James E, Scarbrough, Dean A, Weyers, Jeffrey S, Harrison, Kenneth F, Johnson, Zelpha B, Daniels, Lathan B, Rosenkrans, Charles F, Kellogg, D.Wayne, Hubbell, Donald S

“…Wheat (Triticum aestivum L.), oat (Avena sativa L.) and rye (Secale cereale L.) were overseeded into a dormant bermudagrass (Cynodon dactylon (L.) Pers.) sod…”
Get full text

Cytosine arabinoside, etoposide and aclarubicin (AVA) for the treatment of acute myeloid leukemia (AML) in elderly patients by Staib, P., Lathan, B., Knöppel-Schwark, S., Tesch, H., Voliotis, D., Steinmetz, H. T., Schwonzen, M., Wickramanayake, P. D., Diehl, V.

“…Background: Elderly patients (age ≥ 60 years) with acute myeloid leukemia (AML) have unfavourable prognoses when polychemotherapy regimens are used, because…”
Get full text

Selective growth-inhibition of multidrug-resistant CHO-cells by the monoclonal antibody 265/F4 by EFFERTH, T, LATHAN, B, VOLM, M

Get full text

A Phase-II Study with Idarubicin, Ifosfamide and VP-16 (IIVP-16) in Patients with Refractory or Relapsed Aggressive and High Grade non-Hodgkin's Lymphoma by Engert, A., Schnell, R., Kñpper, F., Reiser, M., Engelhard, M., Wilhelm, M., Lathan, B., Baltes-Engler, S., Winterhalter, B., Scheulen, M. E., Dederichs, B., Tesch, H., Wörmann, B., Diehl, V.

“…We report a phase-II study of idarubicin, ifosphamide and etoposide (IIVP-16) in heavily pretreated patients with relapsed or refractory aggressive…”
Get full text

Combined effect of very early intensification and prolonged post-remission chemotherapy in patients with AML by Büchner, T, Hiddemann, W, Schaefer, U W, Löffler, H, Maschmeyer, G, Ludwig, W D, Aul, C, Lathan, B, Heinecke, A

“…The study combines the effects of prolonged postremission chemotherapy with that of very early intensification. 900 adult patients at all ages with newly…”
Get more information

High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison by Hiddemann, W, Aul, C, Maschmeyer, G, Schönrock-Nabulsi, R, Ludwig, W D, Bartholomäus, A, Bettelheim, P, Becker, K, Balleisen, L, Lathan, B

“…193 patients with relapsed or refractory acute myeloid leukemia (AML) were entered into a prospective randomized comparison of high-dose versus intermediate…”
Get more information

Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute myeloid leukemia: data from the AML Cooperative Group by Büchner, T, Hiddemann, W, Löffler, G, Gassmann, W, Maschmeyer, G, Heit, W, Hossfeld, D, Weh, H, Ludwig, W D, Thiel, E

Get more information

Immunohistochemical detection of P-glycoprotein in normal and malignant tissues: a comparative study of three monoclonal antibodies, JSB-1, C 219 and 265/F4, against different epitopes using frozen and paraffin tissue sections by Bittl, A, Nap, M, Jäger, W, Lathan, B, Lang, N

“…In this study, the reactivity of three different monoclonal antibodies (MAbs) against the multiple-drug resistance (MDR)-related P-glycoprotein (P-170) were…”
Get more information